Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder

Ellison Suthoff,Mark Kosinski,Alix Arnaud,Paul Hodgkins,Handan Gunduz-Bruce,Robert Lasser,Christopher Silber,Abdul J. Sankoh,Haihong Li,Brian Werneburg,Jeffrey Jonas,James Doherty,Stephen J. Kanes,Vijayveer Bonthapally

Journal of Affective Disorders（2022）

引用 8|浏览6

暂无评分

摘要

•Improved SF-36v2 scores in 3 domains and 1 summary score with zuranolone for MDD•SF-36v2 domain scores with zuranolone exceeded minimally important differences.•Improvements in clinician- and patient-rated measures were positively correlated.

查看译文

关键词

Major depressive disorder,Zuranolone,Quality of life,Patient reported outcomes,SF-36v2

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要